Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6ST | P40189 | 5/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 8/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19018653 | 1.00 | IL6ST (0.52) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL7797511 | 1.00 | IL6ST (0.52) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL5500159 | 0.90 | IL6ST (0.54) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL3962683 | 0.89 | IL6ST (0.49) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL3960159 | 0.89 | IL6ST (0.49) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL20536993 | 0.87 | IL6ST (0.49) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL29589364 | 0.87 | IL6ST (0.49) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL14690910 | 0.87 | IL6ST (0.49) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL3967160 | 0.87 | IL6ST (0.49) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL3960613 | 0.87 | IL6ST (0.49) | IL6STPPARANAAAIDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39836-E1 | Macrolide antinfective agents | KOSAN BIOSCIENCES, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1754700-A2 | Synthesis of oligoketides | Kosan Biosciences, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1171446-B1 | MACROLIDE ANTIINFECTIVE AGENTS | KOSAN BIOSCIENCES INC (US) | 2006-09-20 | — | — | EP | disclosed |
| US-7022825-B2 | Polyketides and antibiotics | KOSAN BIOSCIENCES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-6794366-B2 | ERYTHRONOLIDE DERIVATIVES THAT CONTAIN MODIFICATIONS FROM THE NATIVE STRUCTURE AT POSITIONS 13, E.G., 15-(QUINOL-4-YL-ACETAMIDOERYTHROMYCIN A; BACTERICIDES; PRESERVATIVES | KOSAN BIOSCIENCES, INC. | 2004-09-21 | — | — | US | disclosed |
| US-6762168-B2 | ANTIBACTERIAL COMPOUNDS. THE INVENTION CONCERNS MACROLIDE ANTIBIOTICS USEFUL AS ANTIINFECTIVE AGENTS. | KOSAN BIOSCIENCES, INC. | 2004-07-13 | — | — | US | disclosed |
| US-20030207821-A1 | Macrolide antiinfective agents | CHU DANIEL T W (US) | 2003-11-06 | — | — | US | disclosed |
| EP-1345953-A2 | KETOLIDE ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6593302-B2 | Antibiotics | KOSAN BIOSCIENCES, INC. | 2003-07-15 | — | — | US | disclosed |
| US-6590083-B1 | Compounds of given formula; erythromycin derivatives; useful in the treatment of bacterial and protozoal infections and conditions involving gastric motility | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-08 | — | — | US | disclosed |
| EP-1171447-A2 | KETOLIDE ANTIBACTERIALS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1171446-A2 | MACROLIDE ANTIINFECTIVE AGENTS | Kosan Biosciences, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1171448-A2 | MACROLIDE ANTIINFECTIVE AGENTS | Kosan Biosciences, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1144375-A2 | SYNTHESIS OF OLIGOKETIDES | Kosan Biosciences (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044717-A9 | SYNTHESIS OF OLIGOKETIDES | — | 2001-08-23 | — | — | WO | disclosed |
| WO-2001049699-A1 | MACROLIDE ANTIINFECTIVE AGENTS | KOSAN BIOSCIENCES, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2000063224-A2 | MACROLIDE ANTIINFECTIVE AGENTS | KOSAN BIOSCIENCES, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000063225-A2 | MACROLIDE ANTIINFECTIVE AGENTS | KOSAN BIOSCIENCES, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000062783-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000044717-A2 | SYNTHESIS OF OLIGOKETIDES | KOSAN BIOSCIENCES, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207821-A1 | Macrolide antiinfective agents | BECN1, HSPA5, SQSTM1 | IL6ST 1573/4885PPARA 1224/4885NAAA 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.